Internal Medicine, Infectious Disease · Fairfax, VA
NPI
1033130430
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
11211 Waples Mill Road, Suite 200
Fairfax, VA, 22030
Phone (703) 246-9560
Groups this clinician bills Medicare through
Medicare paid, 2024
$222K
78,162 services
Medicare patients, 2024
263
Average age 77
Drug cost, 2024
$725K
474 prescriptions
Company payments, 2025
$28K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Stephen E Weinroth was code 99232 (hospital e&m - subsequent), 477 times for 148 patients. In total Stephen E Weinroth billed 78,162 services in 39 codes, and Medicare paid $222K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-04-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 477 | 148 | $66.38 | $32K |
| 96365 Intravenous Infusion, Hydration | Office | 398 | 59 | $57.14 | $23K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 389 | 56 | $0.52 | $201 |
| J1335 Injection, ertapenem sodium, 500 mg | Office | 370 | 34 | $9.24 | $3,418 |
| 99213 Office E&M - Established | Office | 255 | 76 | $77.26 | $20K |
| 99214 Office E&M - Established | Office | 184 | 101 | $107.33 | $20K |
| 99222 Hospital E&M - Initial | Facility | 152 | 130 | $110.38 | $17K |
| 96366 Intravenous Infusion, Hydration | Office | 27 | 13 | $17.37 | $469 |
| 99204 Office E&M - New | Office | 18 | 18 | $141.85 | $2,553 |
| 99495 Chronic, Principal, and Transitional Care Management | Office | 13 | 13 | $182.82 | $2,377 |
| G0008 Administration of influenza virus vaccine | Office | 11 | 11 | $34.30 | $377 |
| 99215 Office E&M - Established | Office | 11 | 11 | $125.76 | $1,383 |
By year: 2022 $191K for 15,557 services; 2023 $188K for 27,010 services; 2024 $222K for 78,162 services.
Medicare prescription drug claims, 2024
In 2024, the drug Stephen E Weinroth prescribed most often to Medicare patients was Dovato (Dolutegravir Sodium/Lamivudine), with 56 prescriptions and refills. In total Stephen E Weinroth wrote 474 Medicare prescriptions that cost $725K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dovato Dolutegravir Sodium/Lamivudine | 56 | 56 | Under 11 | $167K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 52 | 52 | Under 11 | $214K |
| Methenamine Hippurate Generic | 29 | 55 | 14 | $2,445 |
| Cefuroxime Cefuroxime Axetil | 27 | 27 | 11 | $221 |
| Ciprofloxacin Hcl Generic | 23 | 26 | Under 11 | $169 |
| Trogarzo Ibalizumab-Uiyk | 20 | 20 | Under 11 | $232K |
| Doxycycline Hyclate Generic | 19 | 31 | Under 11 | $588 |
| Valacyclovir Valacyclovir Hcl | 18 | 28 | Under 11 | $770 |
| Ertapenem Ertapenem Sodium | 17 | 17 | Under 11 | $6,890 |
| Disulfiram Generic | 13 | 13 | Under 11 | $1,344 |
| Levofloxacin Generic | 13 | 13 | Under 11 | $42.19 |
| Meropenem Generic | 12 | 12 | Under 11 | $1,440 |
| Atorvastatin Calcium Generic | 11 | 13 | Under 11 | $26 |
Brand drugs: - claims; generic drugs: 298 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Stephen E Weinroth $28K ($28K in general payments such as food, travel and fees) from 15 companies. The largest payer was Gilead Sciences, Inc. with $22K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 46 | $22K |
| Melinta Therapeutics, LLC | 15 | $4,451 |
| Shionogi Inc 4507.T | 17 | $290 |
| ViiV Healthcare Company GSK | 12 | $280 |
| Merck Sharp & Dohme LLC MRK | 7 | $183 |
| Insmed, Inc. INSM | 6 | $148 |
| Abbvie Inc. ABBV | 10 | $138 |
| La Jolla Pharmaceutical Company | 5 | $128 |
| Evoke Pharma, Inc. EVOK | 1 | $125 |
| Pfizer Inc. PFE | 5 | $122 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.